Venomyx Therapeutics cover feature

Venomyx Therapeutics

EpiPen for snakebites: the antivenom of tomorrow!
$233,866 Raised
Ended July 1st
392 Investors

We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum antivenom for snakebites. Conventional antivenom is outdated: it's expensive, labor-intensive, works for a single species of snake, can only be administered in a hospital, must be kept cold, and has a host of negative side effects for the patient. Our first product, Vipax, elegantly solves these problems while being cheaper to produce.

Why you may want to invest
  1. 10x more effective than conventional antivenom.

  2. Our antivenom saved 100% of mice from whole snake venom.

  3. Our antivenom is made in bacteria instead of horses = cheaper and faster to produce.

  4. Since it's made in bacteria, there are fewer risks of negative side effects in humans.

  5. Vipax is stable at room temperatures for portability.

  6. International patent for antivenom composition and methods.

  7. $250K committed to $1.2M round so far.

Learn more about this company

Company Details

Location
La Jolla, CA
Founded
2015
Employees
3

Key Team Members

Deepankar Roy
Founder and COO
Daniel Dempsey
Founder and CEO

Financials

Most recent Fiscal Year

Income Statement

Revenue
$0
Cost of Goods Sold
$0
Gross Profit
$0
Taxes
$0
Net Income
36%
-$158,248

Balance Sheet

Total Assets
35%
$155,226
Cash
89%
$10,226
Accounts Receivable
$0
Short Term Debt
$0
Long Term Debt
102%
$202,500

Other popular startups

Get email updates for the latest investment opportunities
Email
Email